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Abstract
Purpose—The mammalian target of rapamycin (mTOR) is activated in Kaposi sarcoma (KS)
and its inhibitor, rapamycin, has induced KS regression in transplant-associated KS. This study
aimed to evaluate rapamycin's safety and toxicity in HIV-infected individuals with KS receiving
antiretroviral therapy (ART), investigate rapamycin interactions with both protease inhibitor (PI)-
containing and non-nucleoside reverse transcriptase inhibitor (NNRTI)-containing ART regimens,
and assess clinical and biological endpoints including KS response and mTOR-dependent
signaling.
Methods—Seven participants, 4 on PI-based and 3 on NNRTI-based ART, had rapamycin
titrated to achieve trough concentrations of 5-10 ng/mL. Patients were monitored for safety and
KS response. KS biopsies were evaluated for changes in phospho-Ribosomal S6 protein (pRPS6),
and phospho-Akt expression. Interleukin-6 and vascular endothelial growth factor levels, HIV and
KS-associated herpesvirus viral loads, and CD4 counts were monitored.
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Results—Despite pharmacokinetic interactions resulting in >200-fold differences in cumulative
weekly rapamycin doses between participants on PI-containing and NNRTI-containing regimens,
treatment was well tolerated. There were no significant changes in viral loads or cytokine levels;
modest initial decreases in CD4 counts occurred in some patients. Three participants, all on PI-
containing regimens and with higher rapamycin exposure, showed partial KS responses. Three of
four subjects whose biopsies were studied at ≥day 50 showed decreased pRPS6 staining.
Conclusions—Rapamycin appears safe in HIV-infected individuals with KS and can, in some
cases, induce tumor regression and affect its molecular targets. Significant pharmacokinetic
interactions require careful titration to achieve target drug trough concentrations, but may be
exploited to achieve therapeutic benefit.
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Introduction
Recognition that the phosphatidylinositol 3-phosphate kinase/Akt/mammalian target of
rapamycin (PI3K/Akt/mTOR) signaling pathway is dysregulated in many tumor types has
led to numerous clinical trials of rapamycin (sirolimus) derivatives in various cancers, and
their regulatory approval in a few1-4. Although human immunodeficiency virus (HIV)
infection has long been associated with an increased risk of AIDS-defining cancers, and
more recently with an increased risk of certain non-AIDS-defining cancers (NADCs)5, the
clinical use of rapamycin in HIV-infected individuals has focused on its immunosuppressive
properties, chiefly to prevent rejection of solid organ allografts6-8 and HIV-infected patients
were not included in pivotal trials leading to approval of rapamycin analogs for NADC
indications.
Kaposi sarcoma (KS), the most commonly diagnosed AIDS-defining cancer worldwide, is
one of several immunodeficiency-related neoplasms associated with infection with the KS-
associated herpesvirus (KSHV)9. One mechanism by which KSHV may promote
tumorigenesis is via activation of the phosphatidylinositol 3-phosphate kinase/Akt/
mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway, which is
dysregulated in many tumors (reviewed in10). In KSHV-associated tumors, several viral
proteins can activate the PI3K/Akt/mTOR pathway in the absence of host mutations or
deletions11-14.The mTOR executes essential functions with respect to tumor cell growth and
proliferation that result from Akt activation. Its potential as a target for KS therapy was
suggested by the observation that KS regressed in a group of HIV-uninfected renal allograft
recipients whose immunosuppressive therapy was changed from a cyclosporin A-based
regimen to rapamycin, titrated to achieve trough concentrations of 6-10ng/ml, while their
allograft function was not adversely affected15. In these patients, levels of phosphorylated
Akt and p70S6 Kinase (a downstream target of the mTOR:Raptor complex, mTORC1,
which phosphorylates ribosomal S6 protein, RPS6, to enhance translation) were elevated in
pre-rapamycin KS biopsies compared to normal skin from the same individuals. These
observations, supported by mechanistic studies showing direct inhibitory effects of
rapamycin on KSHV-infected tumor cells11,13,16 and indirect, immunomodulatory effects
leading to enhanced recovery of T-cell responses to KSHV17, provided a rationale for
evaluating rapamycin in HIV-associated KS.
Because rapamycin is a substrate for the drug-metabolizing enzyme cytochrome P450 3A4
(CYP3A4) and the efflux transporter P-glycoprotein18,19, we anticipated interactions with
antiretroviral drugs (ART) that inhibit or induce these proteins. Indeed, when this study was
Krown et al. Page 2













initially developed in 2006, we knew of 2 reports in HIV-infected transplant recipients
showing interactions between drugs used to prevent graft rejection and ART6,7. However,
these reports provided insufficient data on which to base firm recommendations about
appropriate rapamycin doses to use together with different ART regimens. We also had
concerns about administering an immunosuppressive agent to individuals infected with an
immunosuppressive virus, but this was tempered by reports that rapamycin inhibits HIV
infectivity and transcription in culture20.
With the foregoing in mind, the AIDS Malignancy Consortium (AMC), a National Cancer
Institute-supported clinical trials group, designed a pilot study, AMC051, to evaluate
rapamycin's safety and toxicity in HIV-infected individuals with KS receiving protease
inhibitor (PI)-based or non-nucleoside reverse transcriptase inhibitor (NNRTI)-based
antiretroviral regimens and to estimate the dose(s) of rapamycin required to achieve trough
rapamycin concentrations between 5 and 10 ng/mL. These aims are consistent with the
goals, articulated by Persad et al21 and endorsed by the AMC, of identifying significant
interactions between new anticancer agents and drugs used to treat HIV infection and
removing barriers to enrollment of HIV-infected cancer patients into clinical trials. As
secondary objectives, we wished to evaluate the clinical response of KS to rapamycin and its




Eligible participants were HIV-infected men or women, ≥18 years old, with stable or
progressing, biopsy-proven KS, who were receiving a stable anti-retroviral regimen of at
least three drugs, one of which had to be a PI or an NNRTI, for ≥12 weeks. At least five
measurable, non-radiated, cutaneous indicator lesions, as well as additional skin lesions for
biopsy, were required. Lymph node, oral, gastrointestinal (GI) and/or lung KS, not requiring
cytotoxic therapy, was permitted. Additional requirements included Karnofsky performance
status (KPS) >60, life expectancy ≥3 months, and ability to provide informed consent and
comply with the protocol. Effective barrier contraception was required of all participants;
women of child-bearing potential were required to have a negative pregnancy test within 72
hours. The protocol and consent form were approved by each of the participating sites’
institutional review boards in accordance with an assurance filed with and approved by the
U.S. Department of Health and Human Services.
The following laboratory parameters were required within 21 days before entry: hemoglobin
≥8.0gm/dL; neutrophils ≥1000 cells/mm3; platelets ≥75,000/mm3; GFR >40 mL/min; total
bilirubin ≤1.5X the upper limit of normal (ULN), with exceptions for elevated indirect
bilirubin in subjects receiving indinavir or atazanavir; AST and ALT ≤2.5 times ULN;
fasting triglycerides ≤400mg/dL (4.5mmol/L), and total cholesterol ≤300 mg/dL (7.8mmol/
L); spot urine protein:creatinine ratio ≤0.5 and/or proteinuria ≤500 mg/day; and, CD4 count
>50 cells/μL and plasma HIV RNA level <400 copies/mL.
Exclusion criteria included prior rapamycin treatment; active infection; prior or concurrent
malignancy except basal cell skin cancer or cervical carcinoma in situ; treatment for
infection or other serious illness within 14 days; infiltrate, cavitation or consolidation on
chest x-ray within 3 months; treatment for KS within four weeks or local therapy to any KS
indicator lesion within 60 days; investigational treatments within four weeks; acute or
chronic liver disease; and/or, Grade III/IV cardiac disease. Nursing or pregnant women were
excluded. Systemic corticosteroids and agents other than ART that would interfere with
rapamycin metabolism or excretion were prohibited.
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The protocol originally specified an initial rapamycin dose of 0.025 mg/kg/day using a
liquid oral formulation (Rapamune®, Wyeth Pharmaceuticals, Inc, Philadelphia, PA) at a
concentration of 1 mg/mL, without a loading dose. We planned to treat 6 evaluable
participants, 3 each on PI-containing and NNRTI-containing antiretroviral regimens. After
the first study participant treated at this dose together with a ritonavir-boosted PI (PI/r)
regimen showed an unacceptably high trough concentration after 7 days, we modified the
starting doses based on analysis of data from the first patient and the literature as follows:
participants receiving a PI/r regimen received 0.0015 mg/kg/day; those receiving a PI
regimen without ritonavir received 0.003 mg/kg/day; and, those on an NNRTI regimen
received 0.05 mg/kg/day. If the calculated daily dosage yielded volumes □0.3ml, the daily
value was multiplied by 2 or 3 to yield a volume of at least 0.3ml; the corresponding doses
were administered three times weekly or twice weekly, respectively. Dosing was
subsequently adjusted based on trough blood rapamycin concentrations to achieve target
concentrations between 5 and 10ng/mL. Responding patients could be treated for up to 12,
four-week cycles. Participants with progressive KS at any time, or those without objective
response after 6 cycles, were removed from study.
Monitoring
Routine clinical and laboratory assessments were performed at baseline, days 8, 15 and 29,
and every 4 weeks thereafter. KS evaluations were performed as described previously22 at
baseline; response was assessed every 4 weeks for the first 3 months, and every 8 weeks
thereafter. Patients completing treatment with stable disease or objective response had their
response status reassessed approximately 30 days after the last rapamycin dose. CD4+ T-
lymphocyte count and HIV VL were measured at baseline, week 4, and then every third
cycle. KSHV VL and cytokines were measured at baseline and Day 15 of cycle 1 and on
Day 1 of cycles 2, 3, 5, 7, 9, and 11. Rapamycin trough concentrations were measured on
Days 8, 15, 21, 29, 43 and 57 and every 4 weeks thereafter. We initially monitored trough
concentrations by liquid chromatography tandem mass spectroscopy (LCMSMS) (Quest
Diagnostics, San Juan Capistrano, CA). However, because results using this method were
not available until ≥3 days after the specimen was obtained, we added backup rapamycin
immunoassays to facilitate recognition of potentially toxic levels. Immunoassays were
performed on an IMx analyser (Abbott Laboratories, Chicago, IL, USA) by microparticle
enzyme immunoassay (MEIA), with results available the same day. Once a participant's
dose stabilized and LCMSMS trough values were consistently within the target range,
backup immunoassays were discontinued. Rapamycin doses were adjusted when trough
concentrations fell outside the target range as follows: new dose = current dose × (midrange
target trough concentration/actual trough concentration), where the midrange target is 7.5ng/
mL.
KS punch biopsies were performed at baseline and again within 14 days of achieving a
trough rapamycin concentration within the target range. Specimens were fixed in 10%
formalin.
KSHV viral load (VL)
Plasma was separated from whole blood using Ficoll-based gradient centrifugation and
100μL was used to obtain genomic DNA using the Abbott m2000 DNA Sample Preparation
System (Abbott Laboratories) according to the manufacturer's protocol. Quantitative real-
time polymerase chain reaction was performed as described 23.
HIV VL was measured using standard commercial assays having a lower limit of sensitivity
of 50 RNA copies/mL.
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Human interleukin-6 (IL6) and vascular endothelial growth factor (VEGF) were measured in
plasma using enzyme-linked immunosorbent assay kits from eBiosciences (San Diego, CA)
and PeproTech (Rocky Hill, NJ), respectively.
Immunohistochemistry (IHC)
Formalin-fixed, paraffin-embedded tumor biopsies were cut into 7μm sections, de-
paraffinized, rehydrated. and incubated in 3% hydrogen peroxide/10% methanol to block
endogenous peroxidase. Samples were boiled for 20min in 1mM EDTA (pH 8.0) and
blocked with 10% horse serum (Vector Laboratories, Burlingame, CA) in PBS/5% BSA/
0.3% TritonX-100 (Blocking Buffer), then incubated with primary antibody diluted 1:100 in
Blocking Buffer overnight at 4°C. The antibodies used were: phospho-RPS6 (pRPS6),
phospho-Akt (Ser473) and phospho-Akt (T308) (Cell Signaling, MA). Primary antibodies
were detected with VectaStain ABC kit (Vector Labs, Burlingame, CA) and NovaRed™.
Sections were counterstained with hematoxylin, mounted, and imaged using a LEICA DM
microscope (Leica GmBH, Heidelberg, Germany) equipped with a 10/0.25 numerical
aperture (NA) or a 40/0.75 NA N plan objective and Leica DPC480 camera.
KSHV latency associated nuclear antigen (LANA) and Ki-67 stains were performed using
the BOND-MAX Autostainer (Leica Microsystems, Bonnockburn, IL) using the
accompanying Bond polymer define detection kit after antigen retrieval with Bond epitope
retrieval solution 2 (Leica Microsystems). The antibodies used were KSHV LANA (clone
LN3; Advanced Biotechnologies, Inc., Columbia, MD) and Ki-67 (MIB-1)
(DakoCytomation, Carpinteria, CA).
Biopsies were analyzed by visual scanning of the entire section. Samples were scored
blinded on a scale of 0 to 4 where 0 indicates no staining and 4 is staining equivalent to the
positive control. No staining (red color) observed in the absence of primary antibody was
used as a negative control. Changes in staining score and KSHV VL from baseline to post-
treatment were evaluated using the Wilcoxon signed rank test.
Results
Patient Characteristics
Characteristics of the seven enrolled participants are shown in Table 1. They uniformly
showed high CD4 T-lymphocyte counts and near-normal KPS. The diagnosis of KS was
confirmed by positive LANA staining in all baseline biopsy specimens (data not shown).
Rapamycin Dose Titration
Table 2 summarizes rapamycin doses and trough levels. All four participants who received
PI/r-containing ART initially overshot the maximum target trough concentration of 10ng/ml
and required multiple adjustments to regulate the dose. Indeed, the first patient, who was
receiving a ritonavir-boosted lopinavir regimen, showed a trough level of 123ng/mL after 7
days of treatment at a rapamycin dose of 2mg once a day. The commercial laboratory
performing the drug assays assumed that the level was an error and refused to release the
data to the treatment site until the assay had been repeated, delaying dosage interruption for
another week, at which time the blood level had reached 172ng/mL. After stopping
rapamycin, blood levels gradually declined to acceptable levels over three weeks. Despite
these high levels, he showed minimal (grade 1) side effects. Although two subjects on
NNRTI-based regimens initially overshot the maximum target trough level, only single
dosage adjustments were needed to achieve consistent trough levels within the target range;
one subject on an NNRTI-based regimen required an increase in the initial dose. As shown
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in Table 2, the eventual stable maintenance doses for the four individuals on PI/r-containing
ART regimens ranged from 0.1mg twice weekly to 0.3mg three times a week, whereas for
participants on NNRTI-based regimens, the range was 2.3 to 6.7mg once a day, a difference
of >200 fold.
Adverse Events
Treatment was generally well tolerated. All patients experienced adverse events, but most
were grade 1. Two patients had serious adverse events: grade 3 infection (dental abscess)
without neutropenia, attributed to a pre-existing condition (root canal) in patient #1 (this
event occurred several months after the rapamycin trough level had fallen to within the
desired target range), and extensive grade 3 superficial vein thrombus requiring
anticoagulation, considered possibly related to rapamycin, in patient #4.
Patient #5 had 2 separate grade 2 infectious episodes without neutropenia, including
pneumonia responsive to oral antibiotics and dermatomal Herpes zoster. Patient #6
developed symptoms of a grade 2 upper respiratory infection, without neutropenia, that
resolved without treatment. Four patients (two each on PI- and NNRTI-based regimens)
experienced triglyceride elevations, with a maximum grade of 1 (1 patient), 2 (2 patients)
and 3 (1 patient).
Effects on markers of HIV Disease
We observed no consistent changes in HIV VL. Four of five participants with undetectable
HIV VLs at baseline showed no change during therapy, whereas one patient showed an
isolated increase at week 40 and again had an undetectable level at week 48. One participant
showed a baseline value just above the limit of assay detection (65 copies/mL), but was not
subsequently tested. Another participant with an undetectable VL at screening was later
discovered to have become non-adherent to antiretroviral treatment in the interval between
screening and initiation of rapamycin, and had an elevated HIV VL at day 1. He
subsequently resumed antiretroviral therapy and his VL remained undetectable from week
16 through week 48.
The median baseline CD4 count was 826 cells/μL (range, 558-1062). CD4 counts remained
>400 cells/μL for the 6 study participants in whom follow-up tests were performed
(FIGURE 1). Five of these 6 patients showed a >10% drop in CD4 count within the first 16
weeks. Afterwards, CD4 counts increased to baseline levels or remained level.
Effects on KSHV plasma VL
At baseline, the median KSHV VL was 214 copies/ml (range, 28-56,653). There were no
significant changes during rapamycin treatment. The median change during treatment was
-138.8 copies/ml (P=0.156).
Therapeutic response (Table 2)
The median treatment duration was 16 weeks (range, 4-49 weeks). Three patients showed
partial KS response after 3 to 9 weeks. Response duration ranged from 43 to 50 weeks.
None of the responding patients relapsed during study treatment or at the 30-day follow-up.
The three patients showing partial response were all receiving PI/r regimens, and were also
the patients showing the highest rapamycin trough levels. Three patients showed stable
disease as the best response and one showed KS progression after 4 weeks. Two stable
patients subsequently showed KS progression at weeks 12 and 17 of study, respectively; the
third patient discontinued study participation at week 14 (relocated to another state) without
having shown KS progression.
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At baseline, the median plasma IL6 concentration was 8.22pg/ml (range, 3.00-23.5) and the
median plasma VEGF concentration was 187ng/ml (range, 40.4-406). No significant
changes in plasma IL6 or VEGF concentrations were observed during treatment (data not
shown).
KS biopsy studies
Figure 2 shows IHC for pRPS6 in KS lesions at baseline. The top right panel shows a
biopsy from subject #6, in which pRPS6 was detected both in KS spindle cells and
endothelial cells lining blood vessels. The other panels show the variation in pRPS6
positivity in baseline biopsies.
All patients had at least one biopsy repeated while receiving rapamycin. Four patients,
including the three who received NNRTI-based regimens and one (subject #3) who received
a PI/r-based regimen, had biopsies repeated between days 22 and 29. All four patients who
received PI/r-based regimens had biopsies performed at day 50 or later. On-treatment
biopsies were assessed for changes from baseline in pRPS6, phospho-Akt (Ser 473) and
phospho-Akt (T308) staining. Although overall, no significant changes were detected in
staining scores, the biopsies of some individuals showed evidence for pRPS6 inhibition.
Figure 3A shows a representative section stained for pRPS6 at baseline, and Figure 3B a
section from the same patient after 50 days on drug. In this individual, decreased pRPS6
reactivity was observed within KS tumor cells and also within overlying epithelium. As
shown in Figure 3C, three of four subjects whose biopsies were studied at day 50 or later –
all of whom received PI/r-based ART regimens – showed decreased pRPS6 staining
compared to baseline. In all four, the on-study staining level was absent (score 0) or minimal
(score 1), suggesting that rapamycin had affected its molecular target.
We saw no significant changes in Akt phosphorylation at either T308 or Ser473, or changes
in Ki-67 or LANA staining upon treatment with rapamycin (data not shown).
Discussion
KS was one of the first clinical manifestations heralding the acquired immunodeficiency
syndrome. Although KS incidence in the U.S. declined after peaking in the 1980s, it has
recently stabilized24,25. At the same time, improved ART has prolonged the lives of many
HIV-infected individuals, resulting in increased numbers of people living with HIV and at
risk for various cancers, including KS. In low-resource settings, particularly sub-Saharan
Africa where rates of both HIV and KSHV infection are much higher than in the U.S. and
antiretroviral therapy has reached only a fraction of affected individuals, KS remains
common26-29. In both high- and low-resource settings, improved KS therapy is needed.
Rapamycin analogs have received U.S. Food and Drug Administration approval for
treatment of renal cell carcinoma, and other tumors have been shown to be sensitive to these
agents1,3 These tumors are considered PI3K/Akt/mTOR addicted. They are characterized
molecularly by high-level phosphorylation of Akt, mTOR and the mTORC1 targets, p70S6
Kinase and RPS6. KS lesions also express phosphorylated Akt15,30 and as shown here in
Figure 1, phosphorylated RPS6. Therefore, KS can be considered a PI3K/Akt/mTOR-
addicted tumor.
Our findings are consistent with those in HIV-negative renal allograft recipients15, and
demonstrate that rapamycin, an allosteric inhibitor of mTORC1, can induce KS regression in
at least some HIV-infected individuals without inducing serious adverse effects. However,
the small sample makes any statement about the efficacy of rapamycin in AIDS-associated
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KS premature. Treatment was, overall, well tolerated even when initial rapamycin trough
levels markedly overshot the intended range. Notably, there was no increase in HIV VL,
which was not unexpected given that HIV replication depends on activated T cells and
active Akt signaling20,31. We did, however, observe modest decreases in CD4 T-lymphocyte
counts in some participants. Because they all had relatively high baseline CD4 T-
lymphocyte counts, the decrease did not result in levels that would raise concern about
susceptibility to opportunistic infections typically associated with advanced HIV disease.
Although three patients experienced infections, they were self-limited and/or easily
treatable, were not AIDS-defining, and may not have been related to rapamycin
administration. A CD4 count decrease of similar magnitude among patients starting at a
lower baseline level could, however, be of concern.
We observed substantial interactions between rapamycin and antiretroviral drugs, most
notably PI/r. Although interactions were expected based on the prior experience in HIV-
infected transplant recipients6,7 their magnitude and the speed with which elevated levels
developed was not, and required marked reduction of the originally planned rapamycin dose
in subjects receiving ritonavir, a particularly potent inhibitor of CYP3A432-37. While it was
possible to suggest a starting dose in these patients, therapeutic monitoring and dose
readjustments were necessary because of the large inter-patient variability in rapamycin
pharmacokinetics and the variable effect of ART on its pharmacokinetics. These types of
interactions have implications for the management of the growing number of HIV-infected
cancer patients with the many anticancer agents whose absorption and/or metabolism are
regulated by CYP enzymes.
The observation that KS regression was documented only in subjects receiving PI/r-based
regimens deserves comment. Given the small sample, this may have been a chance
occurrence. It is possible, however, that increased and/or more sustained rapamycin
exposure accounts for both the improved therapeutic effects and the more consistent
decreases in pRPS6 staining in biopsies from those patients. Alternatively, or in addition,
some of the “off-target” effects of PIs, which include inhibition of Akt activation (reviewed
in 38), may have contributed to the observed therapeutic effects. These possibilities require
further study. Finally, we note that dose-related side effects for rapamycin are not well
defined. Among our patients who inadvertently achieved very high rapamycin levels, it is
not clear that there were resultant adverse effects. A future study with dose escalation to
levels of rapamycin higher than those targeted for chronic immunosuppression in the context
of organ transplantation may be warranted. This study suggests that in patients on PI/r
regimens, much higher, sustained drug levels could be readily achieved.
In conclusion, the results of this study suggest that rapamycin, and potentially other
“rapalogs”, can be safely administered to patients with HIV-infection and cancer.
Rapamycin induced both regression of HIV-associated KS and predicted effects on mTOR
targets in tumor biopsies in some patients. Thus we believe that studies in a larger group of
patients and perhaps involving dose escalation are warranted.
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Changes in CD4 T-lymphocyte counts during rapamycin treatment. Shown are patient CD4
counts in cells per μl on the vertical and time on protocol in days on the horizontal axis. The
different colors represent individual patients.
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Phospho RPS6 (S235/S236) staining at baseline. Shown are representative biopsies from 4
patients prior to treatment. A xenograft tumor that developed after subcutaneous injection of
primary effusion lymphoma (PEL) BC-1 cells was used as a positive control (top left
panel).The red precipitate indicates the presence of phosphorylated RPS6 in a cell. Cells
were counterstained with hematoxylin (blue). Top two panels, 400x magnification, bottom
four panels at 100x magnification.
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Phospho RPS6 (S235/S236) staining before and after exposure to rapamycin. Panels A and
B show representative biopsies at baseline and after 50 days of treatment in subject #5,
respectively. Panel C shows a quantitation of the IHC data for all patients. The intensity
score is shown on the vertical axis and time in days on the horizontal axis. Individual
patients are indicated by different colors. Note that most patients had only two biopsies
(baseline and after either 22-29 or ≥50 days) as specified in the study protocol.
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Male Gender 7 (100)
Non-Hispanic, White 5 (71)
Non-Hispanic, Black 2 (29)
Age (Years)
    N 7
    Mean ± SD 46.3 ± 6.2
    Median 44.0
    Range 39 -55
Absolute CD4 Count (cells/μL)
    N 7
    Mean ± SD 809.0 ±193.9
    Median 826.0
    Range 558 - 1062
HIV Viral Load <50 copies/mL 5 (71)
Extent of KS
    >50 skin lesions 5 (71)
    Tumor-associated edema 6 (86)
    Oral or visceral 0 (0)
HAART Regimen
    Ritonavir-boosted PI-based 4 (57)
    NNRTI-based 3 (43)
Prior KS Treatment 5 (71)
    Liposomal doxorubicin 4 (57)
    Paclitaxel 2 (29)
    Bleomycin/vincristine 1 (14)
    Doxorubicin/bleomycin/vincristine 1 (14)
    Interferon alfa 1 (14)
    IM 862 1 (14)
    Valproic acid 1 (14)
    Halofuginone 1 (14)
    COL-3 1 (14)
    Imatinib 2 (29)
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